DZ2681A1 - Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant. - Google Patents

Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant.

Info

Publication number
DZ2681A1
DZ2681A1 DZ980291A DZ980291A DZ2681A1 DZ 2681 A1 DZ2681 A1 DZ 2681A1 DZ 980291 A DZ980291 A DZ 980291A DZ 980291 A DZ980291 A DZ 980291A DZ 2681 A1 DZ2681 A1 DZ 2681A1
Authority
DZ
Algeria
Prior art keywords
thiazololidine
ethoxyübenzylü
pyridyl
amino
methyl
Prior art date
Application number
DZ980291A
Other languages
English (en)
French (fr)
Inventor
Paul David James Blackler
Michael John Sasse
David C Lee
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2681A1 publication Critical patent/DZ2681A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ980291A 1997-12-16 1998-12-15 Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant. DZ2681A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726566.4A GB9726566D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
DZ2681A1 true DZ2681A1 (fr) 2004-06-20

Family

ID=10823692

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980291A DZ2681A1 (fr) 1997-12-16 1998-12-15 Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant.

Country Status (35)

Country Link
EP (2) EP1040110A1 (ja)
JP (1) JP2002508373A (ja)
KR (1) KR100549142B1 (ja)
CN (3) CN1281453A (ja)
AP (1) AP1365A (ja)
AR (1) AR017214A1 (ja)
AU (1) AU1967999A (ja)
BG (1) BG64988B1 (ja)
BR (1) BR9813600A (ja)
CA (1) CA2314107A1 (ja)
CO (1) CO4980880A1 (ja)
CZ (1) CZ299965B6 (ja)
DZ (1) DZ2681A1 (ja)
EA (1) EA004260B1 (ja)
EG (1) EG22337A (ja)
GB (1) GB9726566D0 (ja)
HR (1) HRP20000408B1 (ja)
HU (1) HUP0100509A3 (ja)
IL (1) IL136424A (ja)
IN (1) IN192487B (ja)
MA (1) MA26580A1 (ja)
MY (1) MY135612A (ja)
NO (1) NO317254B1 (ja)
OA (1) OA11766A (ja)
PE (1) PE20000058A1 (ja)
PL (1) PL341146A1 (ja)
RS (1) RS50126B (ja)
SA (1) SA99191115B1 (ja)
SK (1) SK286618B6 (ja)
TR (2) TR200001799T2 (ja)
TW (1) TW509690B (ja)
UA (1) UA72198C2 (ja)
UY (2) UY25308A1 (ja)
WO (1) WO1999031095A1 (ja)
ZA (1) ZA9811506B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
NZ515167A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
US6806280B1 (en) * 1999-04-23 2004-10-19 Smithkline Beecham P.L.C. Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
US6770133B2 (en) 2000-04-25 2004-08-03 Kyorin Pharmaceutical Co., Ltd. Stable crystal of thiazolidinedione derivative and process for producing the same
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
HUP0301161A3 (en) * 2000-09-26 2005-04-28 Reddy S Res Foundation Hyderab Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
JPH09512249A (ja) * 1994-02-10 1997-12-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 腎臓疾患を治療するためのインスリンセンシタイザーの使用

Also Published As

Publication number Publication date
EP1661895A1 (en) 2006-05-31
EA200000654A1 (ru) 2000-12-25
TR199802625A2 (xx) 1999-10-21
PL341146A1 (en) 2001-03-26
UA72198C2 (en) 2005-02-15
MA26580A1 (fr) 2004-12-20
KR20010033141A (ko) 2001-04-25
KR100549142B1 (ko) 2006-02-03
UY25304A1 (es) 2000-12-29
OA11766A (en) 2005-07-19
BG64988B1 (bg) 2006-11-30
HRP20000408B1 (en) 2008-04-30
CO4980880A1 (es) 2000-11-27
AP1365A (en) 2005-01-26
IL136424A0 (en) 2001-06-14
AP2000001831A0 (en) 2000-06-30
JP2002508373A (ja) 2002-03-19
SK9172000A3 (en) 2001-01-18
NO20003069L (no) 2000-06-15
CZ299965B6 (cs) 2009-01-07
EP1040110A1 (en) 2000-10-04
UY25308A1 (es) 1999-07-19
WO1999031095A1 (en) 1999-06-24
GB9726566D0 (en) 1998-02-11
MY135612A (en) 2008-05-30
SK286618B6 (sk) 2009-02-05
SA99191115B1 (ar) 2006-10-11
TR200001799T2 (tr) 2001-01-22
NO317254B1 (no) 2004-09-27
BR9813600A (pt) 2000-10-10
AR017214A1 (es) 2001-08-22
RS50126B (sr) 2009-03-25
IN192487B (ja) 2004-04-24
PE20000058A1 (es) 2000-02-26
CN101302215A (zh) 2008-11-12
HUP0100509A3 (en) 2002-06-28
NO20003069D0 (no) 2000-06-15
TR199802625A3 (tr) 1999-10-21
HRP20000408A2 (en) 2000-08-31
BG104603A (en) 2001-03-30
CA2314107A1 (en) 1999-06-24
EA004260B1 (ru) 2004-02-26
CN101381367A (zh) 2009-03-11
CN1281453A (zh) 2001-01-24
EG22337A (en) 2002-12-31
IL136424A (en) 2003-12-10
YU36300A (sh) 2004-03-12
AU1967999A (en) 1999-07-05
TW509690B (en) 2002-11-11
HUP0100509A2 (hu) 2002-05-29
ZA9811506B (en) 2000-11-06
CZ20002204A3 (cs) 2000-11-15

Similar Documents

Publication Publication Date Title
DZ2681A1 (fr) Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant.
MA24469A1 (fr) Derives d'acide arylsulfonyhydroxamique, procede pour leur preparation et compositions les contenant
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
FR2670488B1 (fr) Composition pharmaceutique contenant une forme physique particuliere d'un amide heterocyclique et son procede de preparation.
FR2730637B1 (fr) Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
DZ2679A1 (fr) Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant.
EP0485045A3 (en) Mono-n-substituted 1,4,7,10-tetraazacyclododecan-derivatives, process for their preparation and pharmaceutical agent containing them
MA26901A1 (fr) Nouvelle composition pharmaceutique
TNSN94078A1 (fr) Nouvelle formule pharmaceutique
MA26494A1 (fr) Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA23942A1 (fr) Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation
DZ3156A1 (fr) Nouvelle forme polymorphe du sel d'acide 5-Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione, maleique.
HUP9603237A3 (en) Crystalline hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxydo-3-oxo-2,3-dihydro-benzisothiazo-2-yl)-butyl]-amino-methyl}-chromane, process for the preparation thereof and pharmaceutical compositions containing them
DZ2046A1 (fr) Forme cristalline nouvelle du sel d'acide méthanesulfonique d'acide 7-Ä(1alpha,5alpha,6alphaÜ-6-amino-3-azabicycloÄ3.1.0Ühex-3-yl)-6-fluoro -1-(2,4-difluorophényl)-1,4 dihydro-4-oxo-1,8-naphtyridine-3-carboxylique anhydre, procédé pour sa préparationet composition pharmaceutique la contenant.
NZ235234A (en) Renin-inhibiting amino acid derivatives and pharmaceutical compositions thereof
MA26487A1 (fr) Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
BR9609847A (pt) Derivados de N-(4-Benzila-substituída)-2-aminolactam
DZ2680A1 (fr) Dérivé de thiazolidinedione nouveau procédé pour sa préparation et composition pharmaceutique le contenant.
EP0952159A3 (en) Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
FR2651006B1 (fr) Compositions liquides aqueuses d'enzymes
DZ3047A1 (fr) Sel mutuel d'amlopidine et d'atorvastatine, procédé pour sa préparation et compositions pharmaceutiques les contenant.
DK1100775T3 (da) 2,5-Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf og farmaceutiske præparater indeholdende disse